The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2018 | The evolution of MRD-guided therapy for leukemia
Richard Dillon, MBBS, from King’s College London, UK, discusses the current landscape for minimal residual disease (MRD) in acute myeloid leukemia (AML). The evolution of MRD-guided therapies is timely, with MRD moving to being clinically relevant. Dr Dillion mentions multiple studies conclusively proving that MRD is one of the most, if not the most, relevant prognostic factor in AML. In the last few years, MRD measurement has been incorporated into treatment protocols, enabling physicians to choose the best treatment for each individual patient. This interview was recorded at the British Society for Hematology (BSH) 2018 Annual Scientific Meeting, held in Liverpool, UK.
